These discrepancies in relation to EGFR as a predictor of outcome in cervical cancer patients may be due to the variety of techniques and scoring systems used, lack of standardised assays and the different reagents used as well as the sample size and heterogeneity of the samples. This evidence concerns the gene EGFR and cervical carcinoma.